Article
Medicine, General & Internal
Teresa Quattrin, Lucy D. Mastrandrea, Lucy S. K. Walker
Summary: Type 1 diabetes is a chronic disease caused by autoimmune destruction of pancreatic beta cells, and individuals with this disease rely on insulin for survival. Despite advancements, the burden of this disease remains high. Research shows that blocking the immune attack on beta cells holds promise in preserving endogenous insulin production.
Article
Medicine, Research & Experimental
Melanie R. Shapiro, Xiaoru Dong, Daniel J. Perry, James M. McNichols, Puchong Thirawatananond, Amanda L. Posgai, Leeana D. Peters, Keshav Motwani, Richard S. Musca, Andrew Muir, Patrick Concannon, Laura M. Jacobsen, Clayton E. Mathews, Clive H. Wasserfall, Michael J. Haller, Desmond A. Schatz, Mark A. Atkinson, Maigan A. Brusko, Rhonda L. Bacher, Todd M. Brusko
Summary: This study investigates the immune cell subsets in peripheral blood and their changes in individuals with type 1 diabetes (T1D). The researchers found accelerated immune aging in T1D and identified phenotypes associated with the disease. These findings provide insights for biomarker monitoring and therapeutic interventions.
Article
Endocrinology & Metabolism
Xiaofan Jia, Ling He, Dongmei Miao, Kathleen Waugh, Cristy Geno Rasmussen, Fran Dong, Andrea K. Steck, Marian Rewers, Liping Yu
Summary: The study indicates that high-affinity ZnT8A detected by ECL has a higher predictive ability for T1D development, with a higher positive predictive value compared to ZnT8A detected by RBA.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Multidisciplinary Sciences
Colin M. Dayan, Rachel E. J. Besser, Richard A. Oram, William Hagopian, Manu Vatish, Owen Bendor-Samuel, Matthew D. Snape, John A. Todd
Summary: Recent studies have shown that monitoring pancreatic islet autoantibodies and genetic risk assessment can identify most children who will develop T1D, with immunotherapy and primary prevention methods showing success in delaying disease progression. By shifting focus towards early diagnosis and b cell preservation, a future without daily insulin injections for children with T1D is anticipated.
Article
Chemistry, Multidisciplinary
Shaojingya Gao, Yanjing Li, Dexuan Xiao, Mi Zhou, Xiaoxiao Cai, Yunfeng Lin
Summary: The study showed that tetrahedral framework nucleic acids (tFNAs) treatment in NOD mice can induce immune tolerance, protect beta cells, and prevent the onset of type 1 diabetes (T1D) by immunomodulation.
Article
Multidisciplinary Sciences
Helen Larsson, Sofie Albinsson Hogberg, Marcus Lind, Hardis Rabe, Christine Lingblom
Summary: Type 1 diabetes (T1D) is caused by the autoimmune destruction of pancreatic beta cells mediated by T cells. This study found that individuals with long-standing T1D had lower levels of galectin-10(hi) eosinophils, which are T cell suppressors, and a subgroup of these eosinophils were entirely absent in all T1D patients. Additionally, T1D patients had higher levels of CD4+CD8+ T cells and Th17 cells. This study suggests that the absence of galectin-10(hi) eosinophilic subgroup may contribute to the unrestricted killing of insulin-producing beta cells in T1D patients.
SCIENTIFIC REPORTS
(2023)
Article
Medicine, General & Internal
Janet M. Wenzlau, Yong Gu, Aaron Michels, Marian Rewers, Kathryn Haskins, Liping Yu
Summary: Type 1 diabetes (T1D) is a chronic autoimmune disease that attacks the insulin-producing β cells of the pancreatic islets. Our laboratory has recently discovered novel β cell proteins comprising hybrid proinsulin:islet amyloid polypeptide peptides. These peptides can activate T cells in T1D patients and diabetic mouse models, and antibodies to these peptides may serve as valuable early biomarkers of the disease.
Review
Endocrinology & Metabolism
Eddie A. James, Alok V. Joglekar, Amelia K. Linnemann, Holger A. Russ, Sally C. Kent
Summary: In this article, the authors discuss the interface between islet beta cells and immune infiltrates, with a focus on T cells, in the context of T1D. They emphasize the importance of studying pancreatic and immune cell phenotypes and their impact on cell function to gain a comprehensive understanding of T1D disease etiology in humans. They also highlight the active role of beta cells and the critical axis of the T cell-beta cell interface in autoimmune responses.
MOLECULAR METABOLISM
(2023)
Article
Endocrinology & Metabolism
Maria Fasolino, Gregory W. Schwartz, Abhijeet R. Patil, Aanchal Mongia, Maria L. Golson, Yue J. Wang, Ashleigh Morgan, Chengyang Liu, Jonathan Schug, Jinping Liu, Minghui Wu, Daniel Traum, Ayano Kondo, Catherine L. May, Naomi Goldman, Wenliang Wang, Michael Feldman, Jason H. Moore, Alberto S. Japp, Michael R. Betts, Robert B. Faryabi, Ali Naji, Klaus H. Kaestner, Golnaz Vahedi
Summary: This study provides a single-cell atlas of pancreatic islets in patients with type 1 diabetes, revealing potential immune cell activities and cell types. It offers important insights for studying the etiology of diabetes and developing new treatment approaches.
Article
Medicine, Research & Experimental
Chandan Sona, Yu-Te Yeh, Andreas Patsalos, Laszlo Halasz, Xin Yan, Natalia L. Kononenko, Laszlo Nagy, Matthew N. Poy
Summary: Through single-cell RNA sequencing analysis, this study found increased CADM1(+) cells adjacent to CD8(+) T cells in the islets of individuals with T1D and those who were autoantibody-positive, indicating that CADM1-mediated intercellular contact may facilitate the infiltration of cytotoxic T lymphocytes and could serve as a potential therapeutic target for preventing T1D pathogenesis.
Article
Multidisciplinary Sciences
Guanlan Xu, Tiffany D. Grimes, Truman B. Grayson, Junqin Chen, Lance A. Thielen, Hubert M. Tse, Peng Li, Matt Kanke, Tai-Tu Lin, Athena A. Schepmoes, Adam C. Swensen, Vladislav A. Petyuk, Fernando Ovalle, Praveen Sethupathy, Wei-Jun Qian, Anath Shalev
Summary: Oral verapamil lowers inflammatory markers and daily insulin needs in subjects with type 1 diabetes and helps preserve pancreatic beta cell function for at least two years. Verapamil normalizes serum CHGA levels and reverses T1D-induced elevations in circulating proinflammatory T-follicular-helper cell markers. RNA-sequencing further confirms that verapamil regulates the thioredoxin system and promotes an anti-oxidative, anti-apoptotic, and immunomodulatory gene expression profile in human islets.
NATURE COMMUNICATIONS
(2022)
Review
Endocrinology & Metabolism
Ekua W. Brenu, Mark Harris, Emma E. Hamilton-Williams
Summary: This systematic review evaluates novel circulating biomarkers associated with future progression to type 1 diabetes (T1D). The study found that some circulating biomarkers are dysregulated before T1D diagnosis and may be useful in predicting the risk and rate of progression to T1D. However, further research is needed to validate these biomarkers and assess their predictive accuracy.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Immunology
Zhangyan Jing, Yuan Li, Yumeng Ma, Xiaozhou Zhang, Xin Liang, Xudong Zhang
Summary: This review discusses the recent advances in using biomaterials for immunomodulation in the treatment of type 1 diabetes, which can reduce the side effects of immunosuppressants. The applications include targeted delivery, regulation of autoreactive T cells, and restoration of immune tolerance.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Quynh Thi Vu Huynh, Minh Thi Tuyet Trinh, Khang Kim Doan, Ban Tran Ho, Szu-Chuan Shen, Tung Huu Trinh, Thanh Hoa Vo, Nguyen Quoc Khanh Le, Ngan Thi Kim Nguyen
Summary: Asian children in Vietnam are being diagnosed with both type 1 and type 2 diabetes, and the presence of islet autoantibodies makes the diagnosis more complicated. A study found that the prevalence of islet cell autoantibodies (ICAs) and glutamic acid decarboxylase 65 autoantibodies (GADAs) in children with type 1 diabetes was not significantly different from those with type 2 diabetes. Older children with type 1 diabetes were more likely to have ICAs or ICAs and GADAs, while a small proportion of young children had GADAs. However, a significant number of older children with type 2 diabetes were positive for GADAs, and all of them were classified as overweight or obese. The study suggests that further investigation is needed to find better biomarkers or an appropriate time to confirm diabetes type.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Elisa Balmas, Janice Chen, Alex K. Hu, Hannah A. DeBerg, Mario G. Rosasco, Vivian H. Gersuk, Elisavet Serti, Cate Speake, Carla J. Greenbaum, Gerald T. Nepom, Peter S. Linsley, Karen Cerosaletti
Summary: This study analyzed the preservation of IAR CD4+ T cells in patients with new-onset type 1 diabetes in clinical trials and found that the frequency of a unique memory phenotype cell was inversely correlated with C-peptide preservation. This may serve as a biomarker to predict treatment response.
Article
Endocrinology & Metabolism
Caro Minschart, Astrid Lammertyn, Paul Van Crombrugge, Carolien Moyson, Johan Verhaeghe, Sofie Vandeginste, Hilde Verlaenen, Chris Vercammen, Toon Maes, Els Dufraimont, Nele Roggen, Christophe De Block, Yves Jacquemyn, Farah Mekahli, Katrien De Clippel, Annick Van Den Bruel, Anne Loccufier, Annouschka Laenen, Roland Devlieger, Chantal Mathieu, Katrien Benhalima
Summary: The level of gestational weight gain (GWG) during pregnancy is associated with adverse pregnancy outcomes in women with gestational diabetes (GDM) compared to women with normal glucose tolerance (NGT). Low GWG below recommended levels frequently occurs in GDM women without increased risk for adverse outcomes. Excessive GWG is associated with increased risk for neonatal hypoglycemia and worse metabolic profile postpartum in GDM women, and with higher rates of instrumental delivery and larger infants in NGT women.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Editorial Material
Endocrinology & Metabolism
Alice Y. Y. Cheng, Marilia Brito Gomes, Sanjay Kalra, Andre-Pascal Kengne, Chantal Mathieu, Jonathan E. Shaw
Summary: In 2022, the WHO established the first global targets for diabetes mellitus. These targets aim to achieve, by 2030, that 80% of people with diabetes mellitus are diagnosed, 80% of those with diabetes mellitus have good control of blood sugar and blood pressure, 60% of those over 40 receive statin treatment, and 100% of those with type 1 diabetes mellitus have access to affordable insulin and blood glucose monitoring.
NATURE REVIEWS ENDOCRINOLOGY
(2023)
Article
Pediatrics
Mohamed Ghalwash, Vibha Anand, Olivia Lou, Frank Martin, Marian Rewers, Anette-G Ziegler, Jorma Toppari, William A. Hagopian, Riitta Veijola
Summary: Screening for islet autoantibodies in adolescents aged 10-18 can effectively predict the development of type 1 diabetes, allowing for education and prevention measures.
LANCET CHILD & ADOLESCENT HEALTH
(2023)
Article
Obstetrics & Gynecology
Kaat Beunen, Nancy Van Wilder, Dominique Ballaux, Gerd Vanhaverbeke, Youri Taes, Xavier-Philippe Aers, Frank Nobels, Joke Marlier, Dahae Lee, Joke Cuypers, Vanessa Preumont, Sarah E. Siegelaar, Rebecca C. Painter, Annouschka Laenen, Pieter Gillard, Chantal Mathieu, Katrien Benhalima
Summary: This study aims to evaluate the efficacy, safety and cost-effectiveness of the MiniMed (TM) 780G HCL system in pregnant women with T1D. It is an international, open-label, randomized controlled trial that will compare the MiniMed (TM) 780G HCL system to standard of care. The primary outcome is the time spent within the pregnancy glucose target range.
BMC PREGNANCY AND CHILDBIRTH
(2023)
Review
Endocrinology & Metabolism
Katrien Benhalima, Kaat Beunen, Sarah E. Siegelaar, Rebecca Painter, Helen R. Murphy, Denice S. Feig, Lois E. Donovan, Sarit Polsky, Elizabeth Buschur, Carol J. Levy, Yogish C. Kudva, Tadej Battelino, Lene Ringholm, Elisabeth R. Mathiesen, Chantal Mathieu
Summary: Maintaining glucose concentrations within target, appropriate gestational weight gain, lifestyle management, and using antihypertensive treatment and low-dose aspirin if necessary can reduce the risk of complications in pregnancies complicated by type 1 diabetes. Hybrid closed-loop insulin delivery systems show promise as a treatment option during pregnancy.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Hiddo J. L. Heerspink, Andreas L. Birkenfeld, David Z. I. Cherney, Helen M. Colhoun, Linong Ji, Chantal Mathieu, Per-Henrik Groop, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler, Katherine R. Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F. Scheerer, Peter Kolkhof, Janet B. McGill
Summary: This study aims to evaluate the efficacy and safety of Finerenone in type 1 diabetes and chronic kidney disease (CKD). Finerenone could potentially become the first registered treatment for CKD associated with type 1 diabetes in almost 30 years.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)
Article
Endocrinology & Metabolism
Chantal Mathieu, Alice Wiedeman, Karen Cerosaletti, S. Alice Long, Elisavet Serti, Laura Cooney, Joan Vermeiren, Silvia Caluwaerts, Karolien Van Huynegem, Lothar Steidler, Sven Blomme, Pieter Rottiers, Gerald T. Nepom, Kevan C. Herold
Summary: The oral delivery of AG019 was found to be well tolerated and safe as a monotherapy and in combination with teplizumab in patients with type 1 diabetes. The treatment did not interfere with the safety profile of teplizumab and may have additional biological effects, including changes in preproinsulin-specific T cells. Preliminary data support further studies with AG019 alone or in combination with teplizumab or other systemic immunotherapies for type 1 diabetes.
Review
Endocrinology & Metabolism
Chantal Mathieu, Iraj Ahmadzai
Summary: This review examines the use of GLP-1 receptor agonists, specifically in type 1 diabetes, and concludes that they can lower weight and required insulin doses. However, their effects on glucose control and hypoglycemia vary depending on study protocols. Side effects include gastrointestinal complaints. The potential use of GLP-1 receptor agonists in other forms of diabetes is briefly discussed, but current evidence is limited.
Article
Endocrinology & Metabolism
Robert Moulder, Tommi Valikangas, M. Karoliina Hirvonen, Tomi A. Suomi, Caroline A. Brorsson, Niina Lietzen, Sylvaine F. A. Bruggraber, Lut Overbergh, David B. Dunger, Mark Peakman, Piotr J. Chmura, Soren Brunak, Anke M. Schulte, Chantal Mathieu, Mikael Knip, Laura L. Elo, Riitta Lahesmaa
Summary: There is a growing need for markers that could indicate the decline in beta cell function in type 1 diabetes. This study evaluated a panel of proteins in serum from newly diagnosed individuals and found associations between certain proteins and beta cell function. The findings suggest that these proteins may be useful in future studies of beta cell function in type 1 diabetes.
Editorial Material
Endocrinology & Metabolism
Mark A. Atkinson, Michael J. Haller, Desmond A. Schatz, Manuela Battaglia, Chantal Mathieu
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Paul W. Franks, William T. Cefalu, John Dennis, Jose C. Florez, Chantal Mathieu, Robert W. Morton, Martin Ridderstrale, Henrik H. Sillesen, Coen D. A. Stehouwer
Summary: Cardiometabolic disease poses a major threat to global health. Precision medicine has the potential to reduce the burden of this disease cluster and improve evidence-based medicine. It requires a well functioning system involving various stakeholders and relies on powerful computing infrastructure and research methods for analysis of large-scale data.
LANCET DIABETES & ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Katharina Warncke, Alexander Eckert, Ezio Bonifacio, Peter Achenbach, Olga Kordonouri, Thomas Meissner, Ute Ohlenschlaeger, Walter Bonfig, Anette-G. Ziegler, Reinhard W. Holl
Summary: This study aimed to determine whether subgroups of childhood diabetes are associated with diabetes-specific complications and could be a basis for personalised therapies. The researchers found that subgrouping of childhood diabetes at diagnosis could provide prognostic value for the development of acute and chronic diabetes-specific complications.
Meeting Abstract
Endocrinology & Metabolism
S. Charleer, S. Fieuws, T. Boone, C. De Block, N. Bolsens, F. Nobels, K. Mikkelsen, C. Mathieu, P. Gillard
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Meeting Abstract
Endocrinology & Metabolism
S. Charleer, C. De Block, N. Bolsens, L. Van Huffel, F. Nobels, C. Mathieu, P. Gillard
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)
Meeting Abstract
Endocrinology & Metabolism
C. Mathieu
DIABETES TECHNOLOGY & THERAPEUTICS
(2023)